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Coxsackievirus B3 (CVB3) has potential as a new oncolytic agent for the
treatment of cancer but can induce severe pancreatitis. Here, we inserted tar-
get sequences of the microRNA miR-375 (miR-375TS) into the 50 terminus of
the polyprotein encoding sequence or into the 30UTR of the CVB3 strain
rCVB3.1 to prevent viral replication in the pancreas. In pancreatic EndoC-
bH1 cells expressing miR-375 endogenously, replication of the 50-miR-375TS
virus and that of the 30-miR-375TS virus was reduced by 4 3 103-fold and
3.9 3 104-fold, respectively, compared to the parental rCVB3.1. In colorectal
carcinoma cells, replication and cytotoxicity of both viruses were slightly
reduced compared to rCVB3.1, but less pronounced for the 30-miR-375TS
virus. Thus, CVB3 with miR-375TS in the 30UTR of the viral genome may
be suitable to avoid pancreatic toxicity.
Keywords: cancer therapy; colorectal cancer; coxsackievirus B3;
microRNA; oncolytic virus
Coxsackievirus B3 (CVB3) is a nonenveloped virus of
the picornaviridae family, with an icosahedral capsid
and a positive-sense, single-stranded RNA genome
with a length of about 7.4 kb [1]. It has a short repli-
cation cycle of only 6–8 h and produces huge amounts
of progeny virus [2]. In humans, the virus infects the
gastrointestinal tract and typically induces local intesti-
nal disease with mild flu-like symptoms [3]. Under cer-
tain circumstances, CVB3 can pass the local barrier of
the intestine and spread via the bloodstream to other
organs where it replicates to high titers and induces
inflammatory disease, most commonly myocarditis
[4,5], pancreatitis [6], and aseptic meningoencephalitis
[7,8]. CVB3 infection usually resolves by itself, but
occasionally it progresses to severe disease which can
have a fatal outcome. There are many different strains
of CVB3 with different phenotypic characteristics,
leading to different courses of infection [8–12].
In 2012, the oncolytic activity of CVB3 was first
described by Miyamoto et al. [13]. Intratumoral
injection of the CVB3 Nancy strain suppressed
growth of subcutaneous human non–small-cell lung
carcinomas in mice. However, the virus also induced
mild hepatitis, myocarditis [13], and later pancreatitis
was also observed [14]. More recently, we reported
growth inhibition of subcutaneous human colorectal
carcinomas in mice following intratumoral injection
of three different CVB3 strains [15]. Two of the three
strains (31-1-93 and Nancy) also induced severe pan-
creatitis and myocarditis [15]. A third study reported
strong oncolytic activity in endometrial cancer in vivo
using the CVB3 strain CV-B3/2035A which was
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763FEBS Letters 594 (2020) 763–775 ª 2019 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
isolated from a throat swab of a patient with head,
foot, and mouth disease. The virus did not induce
significant treatment-related toxicity and mortality in
nude mice, despite the fact that the virus was
detected at moderate levels in the heart, lung, and
kidney [12].
MicroRNAs (miRs) are small noncoding RNAs
which are endogenously expressed in eukaryotic cells
and processed to an ~ 22 bp long RNA duplex from a
premature precursor with hairpin structure containing
an imperfectly base-paired stem [16,17]. One strand of
these mature miR bind to cognate miR target
sequences (miR-TS) in cellular mRNAs, inducing post-
transcriptional repression of protein synthesis [18].
Many miRs are cell-, tissue-, and organ-specifically
expressed, and the cellular abundance of the miR var-
ies greatly [19,20]. It has been shown that by insertion
of corresponding miR-TS into virus genomes, replica-
tion of the virus can be suppressed in a tissue-specific
manner [21–24]. To optimize the suppression, two to
four copies of a miR-TS or a combination of different
miR-TS are commonly inserted into the viral genome
[23,24]. Moreover, unlike cellular genes, miR-TS in
oncolytic viruses are completely complementary to the
cognate miR which enables endonucleolytic cleavage
of the miR-TS by argonaut 2 [25] and correspondingly
increases the efficiency of target suppression [23,26]. In
picornaviruses, the site of miR-TS insertion within the
viral genome seems to be a further aspect critically
influencing virus suppression. Previous published stud-
ies successfully inserted miR-TS within the 50 and
30UTRs of the viral genome [14,23,27]. However, it
has also been shown that certain sections within the
50UTR and the 30UTR do not tolerate miR-TS inser-
tion [28].
Here, we report that insertion of miR-TS of the
pancreas-specifically expressed miR-375 into the 50 ter-
minus of the CVB3 polyprotein encoding sequence or
into the 30UTR immediately downstream of the stop
codon of the polyprotein is well tolerated by the virus.
Both viruses replicate poorly and lose their cytotoxic-
ity in pancreatic cells expressing miR-375, while retain-
ing their replication competence in the targeted
colorectal cancer cells. However, when comparing the
two viruses, CVB3 containing the miR-TS in the
30UTR showed improved performance.
Materials and methods
Cell lines
HEK293T (human embryonic kidney) cells were cultured in
high glucose Dulbecco’s modified Eagle’s medium (DMEM;
PAA Laboratories GmbH, C€olbe, Germany) supplemented
with 1% sodium pyruvate, 1% L-glutamine, 10% FCS (c.c
pro GmbH, Oberdorla, Germany), and 1% each of peni-
cillin and streptomycin (P/S; Sigma, Munich, Germany).
HeLa cells (human cervical carcinoma) were cultured in
modified Eagle0s medium (MEM) complete medium, which
consists of MEM supplemented with 2 mM L-glutamine,
5% FCS, 1% NEAA, 0.02 M Hepes buffer, and 1%P/S.
EndoC-bH1 cells [29] were cultured in DMEM, low glucose
(1 gL1), containing 2% BSA (fraction V), 10 mM nicoti-
namide, 5.5 lgmL1 transferrin, 6.7 ngmL1 sodium
selenite, 50 lM b-mercaptoethanol, 100 UmL1 penicillin
(P), and 100 lgmL1 streptomycin. Colorectal carcinoma
cell lines DLD1 and Colo320 were grown in RPMI 1640
supplemented with 10% FCS, 1% penicillin-streptomycin,
1% L-glutamine, and 1 mM Na-pyruvate (Invitrogen,
Karlsruhe, Germany). Caco-2 cells were cultured in
DMEM supplemented with 10% FCS, 1% P/S, 1% 2 mM
L-glutamine, and 2% sodium pyruvate.
Plasmids
For the construction of CVB3 cDNA plasmids bearing
miR-TS, the plasmid pMKS1 [2], kindly provided by
Lindsay Whitton (Scripps Research Institute, La Jolla,
CA, USA) was used. It contains the sequence of the
CVB3 clone H3 [11], which was modified by insertion of a
SfiI site and an artificial protease cleavage site immedi-
ately downstream of the CVB3 polyprotein initiation
codon. To insert miR-375TS into the 30UTR of CVB3,
three tandem copies of the miR-375TS and flanking
sequences were generated by gene synthesis (Thermo
Fisher Scientific, GENEART GmbH, Regensburg, Ger-
many) subcloned and inserted into pMKS1 via ClaI/StuI
restriction sites. The plasmid was named pMKS1-30-375TS
(+). To insert miR-375TS into the 50 terminus of the
CVB3 polyprotein coding region, the synthesized miR-
375TS and flanking sequences were subcloned and inserted
in frame via AsiSI and PmeI, which were inserted into the
SfiI site of pMKS1. The resulting plasmid was termed
pMKS1-50-375TS(+).The same procedure was used to
insert three copies of miR-375TS in the inverse orientation
into the 30UTR and at 50 terminus of the CVB3 polypro-
tein coding region. The plasmids were named pMKS1-30-
375TS(-) and pMKS1-50-375TS(-), respectively. Two con-
trol plasmids, pMKS1-30-39TS(+) and pMKS1-50-39TS(+),
were also generated as described above. They each contain
three copies of miR-TS of cel-miRNA-39 from Caenorhab-
ditis elegans, which has no homologous miR in mammals
[30], in the sense orientation in the 30UTR and at the 50
terminus of the CVB3 polyprotein coding region, respec-
tively. The plasmids pCMV-MIR-375 expressing miR-375
and pCMV-MIR-216a expressing miR-216a were
purchased from OriGene (OriGene Technologies Inc.,
Rockville, MD, USA).
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Viruses
rCVB3.1, CVB3-375TS(3+), CVB3-375TS(3), CVB3-
375TS(5+), CVB3-375TS(5), CVB3-39TS(5+), and CVB3-
39TS(3+) were generated by transfection of plasmids
pMKS-1, pMKS1-30-375TS(+), pMKS1-30-375TS(),
pMKS1-50-375TS(+), pMKS1-50-375TS(), pMKS1-30-
39TS(+), and pMKS1-50-39TS(+) into 80% confluent
HEK293T cells using Polyethylenimine Max (Polysciences,
Inc., Warrington, PA, USA) and amplified as described
[15], and then stored at 80 °C until use.
Growth curves
HeLa cells were seeded in 24-well plates and infected the
next day at an MOI of 0.01 with the CVB3 variants at a
confluence of 90% in 500 µL of MEM. Cells were incu-
bated for 2 h at 37 °C and afterward 500 µL of MEM
complete medium was added. After 2, 4, 8, 24, and 48 h
the samples were frozen and thawed twice, centrifuged, and
the supernatant was analyzed by plaque assay on HeLa cell
monolayers as described below. Plaques sizes were mea-
sured with a caliper.
Viral plaque assay
HeLa cells were cultured in 24-well cell culture plates as
confluent monolayers. After 24 h, medium was removed,
and cells were incubated for 30 min with serial ten-fold
dilutions of supernatants, harvested from virus-infected cell
lines after three freeze/thaw cycles and overlaid with agar
containing MEM. Three days later, the cells were stained
with 0.5% MTT/PBS (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Sigma-Aldrich, Steinheim,
Germany).
Transfection of MiR expression plasmids
HEK293T cells were seeded in 6-well plates and 24 h later,
at a confluence of 70–90%, they were transfected with miR
expression plasmids using Polyethylenimine MAX 40K.
XTT cell viability assay
XTT assay was carried out as suggested by the supplier
(Roche Diagnostics, Mannheim, Germany). Briefly,
EndobC-H1, DLD-1 cells and Caco-2 cells were seeded in
96-well plates and infected at an MOI of 100 (DLD1 cells),
1 (EndobC-H1), or 0.01 (Caco-2 cells) with recombinant
CVB3 when they reached a confluence of 90%. Cell viabil-
ity was measured at 144 h (DLD1 cells), 72 h (Caco-2
cells), and 48 h (EndobC-H1) after infection with recombi-
nant CVB3 with the TriStar2 LB 942 Modular Multimode
Microplate Reader (Berthold Technologies, Bad Wildbad,
Germany) or Infinite M200 Pro (Tecan, M€annedorf,
Switzerland).
Quantification of miR-375
Total RNA from cells was isolated with TRIZOL (Life
Technologies GmbH, Darmstadt, Germany) according to
the manufacturer’s instructions. Expression levels of miR-
375 were determined by utilizing the TaqMan gene expres-
sion master mix and specific FAM-tagged TaqMan gene
expression assays for hsa-miR-375 (assay ID: 000564), both
from Life Technologies. Equal loading of RNA was deter-
mined by the measurement of snU6RNA expression as
described [31]. Real-time PCR was performed in a FX96
Real-Time System combined with a C1000 Thermal Cycler
(Bio-Rad, Hercules, CA, USA). The PCR reactions were
carried out in triplicates, and expression values of miR-375
were determined by the DDCt calculation method.
Western blot analysis
Cells were treated with lysis buffer (20 mM TRIS/HCl, pH
8.0, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1%
protease inhibitor cocktail) (Sigma-Aldrich, Taufkirchen,
Germany) and 1% phosphatase inhibitor cocktail (Cal-
biochem, San Diego, CA, USA). Protein concentration was
measured by a BCA assay (Thermo Fisher Scientific, Wal-
tham, MA, USA). Cell extracts were separated by SDS/
PAGE and immunoblotted as described [32]. Primary anti-
body anti-c-tubulin was from Sigma-Aldrich and anti-
eIF4G, cleaved caspase 3, and anti-PARB from Cell Signal-
ing Technology (Danvers, MA, USA). The monoclonal
anti-VP1 was generated against VP1 from CVB5 strain
Faulkner. For detection of CVB3 VP1, c -tubulin, PARP,
cleaved caspase 3, and elF4G, the membrane was blocked
with 5% dry milk/PBS-T and subsequently incubated at
4 °C overnight with the respective antibodies. After wash-
ing three times with PBS-T, the membrane was incubated
with goat anti-mouse and anti-rabbit IgGs conjugated to
horseradish peroxidase (Bio-Rad) in 5% dry milk/PBS-T
for 1 h. Magic MarkXP (Thermo Fisher Scientific) was
used as a molecular weight marker to determine size of
detected proteins after western blotting. Chemiluminescence
was performed using the Supersignal West Pico Substrate
(Thermo Fisher Scientific) and detected with Imager 600
from GE Healthcare (Chalfont St Giles, UK).
Statistics
Statistical analysis was performed with GRAPHPAD PRISM
5.03 (GraphPad Software, Inc., La Jolla, CA, US). Results
are expressed as means  SEM. Statistical significance was
determined by an unpaired Student’s t-test. All differences
were considered statistically significant at a P of < 0.05.
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Results
Expression of miR-375 in pancreatic and
colorectal cell lines
The effectiveness of miR-mediated suppression of
oncolytic viruses strongly depends on the level of miR
expression. In fact, the miR must be highly expressed
in tissues where the virus is to be suppressed, while its
expression must be low or absent in the targeted can-
cer cells. The miR-375 is the most abundantly
expressed miR in the pancreas and is absent or only
expressed at very low levels in other tissues [19,33],
making it a promising candidate for development of
miR-targeted pancreas-attenuated oncolytic CVB3.
Using RT-PCR analysis, we confirmed high expression
of miR-375 in the murine pancreas and found similar
miR-375 expression levels in the pancreatic cell line
EndoC-bH1. In contrast, much lower miR-375 expres-
sion was detected in the colorectal carcinoma cell lines
DLD1 (220-fold), Caco-2 (1200-fold), and Colo320
(1 000 000-fold), as well as the miR-375 expression
levels in the CVB3 producer cell lines HeLa and 293T
were about 104- and 105-fold lower than in EndoC-
bH1 cells and the murine pancreas (Fig. 1A). Thus, we
chose miR-375 for further investigations.
Construction of miR-375TS containing CVB3
To investigate whether replication of miR-375-targeted
CVB3 can be inhibited by miR-375, we inserted three
copies of a target site with complete complementary to
the miR-375 (miR-375TS) into the cDNA of the
CVB3 variant rCVB3.1 [2]. The miR-375TSs were
inserted into the virus genome, either immediately
downstream of the start codon at the 50 terminus of
the CVB3 polyprotein coding region or immediately
downstream of the stop codon in the 30UTR, in both
cases embedded in stuffer sequences and in both the
forward (+) and inverted orientation () (Fig. 1B).
Both orientations were created to elucidate whether
miR-375-induced inhibition differs when the plus- or
the minus-strand replication intermediate of CVB3 is
targeted by miR-375. As controls, two recombinant
CVB3s were produced containing three copies of miR-
39TS of miR cel-miR-39 from C. elegans, which has
no homologue in mammals, in the above-mentioned
sites of the viral genome, in each case in the plus
strand of the CVB3 genome (Fig. 1B).
After production of viruses in HEK293T and HeLa
cells, the size of virus plaques was investigated. For
CVB3 with miR-TS in the 30UTR, we observed that
plaque size of CVB3-375TS(3) was similar to that of
the parental rCVB3.1, whereas the plaques were
slightly smaller in CVB3-375TS(3+) and in the control
virus CVB3-39TS(3+). Differences in plaque sizes were
also observed for CVB3 containing the miR-TS in the
50 terminus of the viral polyprotein coding region,
whereas CVB3-375TS(5+) and the control virus CVB3-
39TS(5+) showed similar plaque size as rCVB3.1, and
CVB3-375TS(5) showed distinctly smaller plaques
(Fig. 2A). To further compare growth kinetics of miR-
TS viruses, we next generated growth curves in highly
susceptible HeLa cells for each virus over a 48-h inves-
tigational period. The 30UTR CVB3-375TS(3) and
the control virus CVB3-39TS(3+) showed slightly
delayed, and CVB3-375TS(3+) moderately delayed,
growth within the first 24 h after infection compared
to rCVB3.1. However, after 48h the titers of the three
miR-375TS viruses were similar to those of rCVB3.1,
indicating the decrease in growth rate was limited to
the first 24 h. Similar was seen for viruses with miR-
TS at the 50 terminus of the CVB3 polyprotein coding
region. All miR-TS viruses of this group showed mod-
erately reduced growth within the first 24 h after infec-
tion. However, while 48 h after infection the
differences in virus titers between CVB3-375TS(5+),
the control virus CVB3-miR-39TS(3+), and the paren-
tal rCVB3.1 disappeared, the titers of CVB3-375TS
(5) remained about one log10 below the titers of
rCVB3.1 (Fig. 2B).
Taken together, the data indicate that insertion of
miR-TS into the 30UTR or into the 50 terminus of the
polyprotein coding region can negatively affect the
growth of CVB3. In particular, the CVB3 variant con-
taining miR-375TS in the viral minus stand at the 50
terminus of the CVB3 polyprotein coding region
showed greatly impaired growth.
CVB3-375TS(3+) is inhibited more strongly than
CVB3-375TS(5+) by transiently transfected miR-
375 in HEK293T cells
To elucidate whether the CVB3-375TS can be inhibited
by miR-375 and whether there are differences between
the constructs, next we transfected HEK293T cells
with miR-375 and infected the cells 24 h later at an
MOI of 0.1 with miR-375TS containing CVB3 or with
the miR-39TS control viruses. As detected by real-time
RT-PCR, miR-375 was highly expressed at the time
point when the cells were infected with CVB3
(Fig. 3A). Plaque assays carried out 24 h after CVB3
infection showed there was no inhibition of CVB3-
375TS(5) and CVB3-375TS(3), indicating that
the negative-strand replication intermediate of virus
could not be targeted by miR-375. In contrast, both
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CVB3-375TS(3+) and CVB3-375TS(5+) were strongly
inhibited by miR-375TS, but reduction of virus repli-
cation was stronger for CVB3-miR375TS(3+) than for
CVB3-375TS(5+) (28- vs 6.6-fold) (Fig. 3B).
CVB3-375TS(3+) is suppressed more strongly in
pancreatic EndoC-bH1 cells than CVB3-375TS(5+)
Having demonstrated inhibition of CVB3-375TS(3+)
and CVB3-375TS(5+) in cells expressing exogenously
introduced miR-375, we next analyzed these viruses
for replication in pancreatic EndoC-bH1 cells, which
express miR-375 endogenously. EndoC-bH1 cells were
infected at an MOI of 1 and analyzed 24 h later. As
shown in Fig. 4A, the titers of CVB3-375TS(3+) and
CVB3-375TS(5+) were 7700-fold and 407-fold lower
compared to the miR-39TS control viruses and even
39 000-fold and 4000-fold lower than the parental
rCVB3.1, respectively. These data were confirmed by
the measurement of CVB3 VP1 expression. As shown
Fig. 1. Expression of miR-375 in different cell lines and the murine pancreas and the structure of the CVB3 genomes containing miR-
TS. (A) Expression of miR-375 in different human cell lines and the murine pancreas. Expression levels of miR-375 were determined by
qRT-PCR in HeLa and HEK293T cell lines; in the colorectal carcinoma cell lines Colo320, DLD1, and Caco-2; in the pancreatic cell line
EndoC-bH1; and in the murine pancreas. The data were normalized against U6snRNA and are shown relative to the expression of miR-
375 in EndoC-bH1 cells which was set as 1. Means  SEM are displayed from one experiment performed in triplicate. (B) Structure of
the genomes of miR-375TS and miR-39TS containing CVB3. In each virus, three tandem repeats of the miR-375TS or the miR-39TS
were inserted into the viral genome of the CVB3 variant rCVB3.1 [2]. MiR-375TS and miR-39TS were inserted either downstream of the
CVB3 polyprotein initiation codon [(5+)- and (5)-viruses] or downstream of the stop codon of the CVB3 polyprotein into the 30UTR
[(3+)- and (3)-viruses] of the viral genome in the sense orientation [(5+)-viruses] to target the plus strand of CVB3 or in antisense
orientation [(5)-viruses] to target the CVB3 minus-strand intermediate. Note: Stuffer sequences flanking miR-TS contain multiple
cloning sites and were inserted during cloning of the miR-TS into the viral genome. The miR-39 is not expressed in mammals.
Therefore, control viruses containing the corresponding miR-39TS are not targeted in mammals. The miR-TS at the 50 terminus of the
CVB3 polyprotein are cloned in frame and therefore form a part of the CVB3 polyprotein. The indicated artificial picornavirus protease
cleavage site ensures that the translated sequences of miR-375TS and miR-39TS are released from the polyprotein during the course
of viral replication [2].
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by western blotting, VP1 expression was not detected
in cells infected with miR-375TS-containing viruses,
whereas miR-39TS control viruses showed abundant
VP1 expression (Fig. 4B). In accordance with the lack
of VP1 expression and strongly reduced virus replica-
tion, EndoC-bH1 cells infected with CVB3-375TS(5+)
and CVB3-375TS(3+) showed lower expression levels
of the CVB3 2A protease target protein elF4G and
apoptosis markers PARP and caspase 3 compared to
those in the uninfected control cells (Fig. 4B). More-
over, both CVB3-375TS(3+) and CVB3-375TS(5+) did
not induce cytotoxicity in EndoCb-H1 cells, whereas
the control viruses induced pronounced lytic infection
(Fig. 4C). The data indicate that both miR-375TS
viruses were efficiently suppressed by endogenously
expressed miR-375. However, determination of virus
titers reveals a distinctly stronger suppression of
CVB3-375TS(3+).
Fig. 2. Plaque size and growth kinetics of miR-TS-bearing CVB3 and parental CVB3 variant rCVB3.1. (A) Plaque sizes. Plaque sizes of
indicated miR-TS viruses were determined by plaque assays on HeLa cell monolayers. Upper panel shows representative images of viral
plaques (white dots) with an average plaque diameter of 20–45 counted plaques  SEM determined in two experiments. Lower panel
presents the graphical representation of plaque diameter. The mean values  SEM are displayed from two experiments and 20–45 counted
plaques. Significance: *P < 0.05, ***P < 0.001; n.s. not significant. (B) Growth curves. HeLa cells were infected at an MOI of 0.01 with
indicated miR-TS CVB3 or rCVB3.1, and the generation of virus progeny was measured by plaque assay 2, 4, 8, 24, and 48 h later. Upper
graph shows recombinant CVB3 with miR-TS in the 30UTR, and lower graph shows recombinant CVB3 with miR-TS at the 50 terminus of
the CVB3 polyprotein encoding sequence. Results are shown as mean values  SEM and reflect two experiments, one with two and one
with four replicates.
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CVB3-375TS(3+) replicates better and induces
more cytotoxicity in colorectal carcinoma cells
lines than CVB3-375(5+)
Finally, we investigated whether insertion of miR-
375TS into the viral genome affects replication and
cytotoxicity of respective viruses in colorectal carci-
noma cell lines. Therefore, the susceptible colorectal
carcinoma cell line Caco-2 was infected with an MOI
of 0.01 and the more resistant cell line DLD1 with an
MOI of 100 of CVB3-375TS(3+) and CVB3-375TS(5+)
and the control viruses CVB3-39TS(3+), CVB3-39TS
(5+), and rCVB3.1. Determination of virus titers by
plaque assay 48 h after infection showed that in both
cell lines, the replication of CVB3-375TS(3+) was
slightly lower than the replication of parental rCVB3.1
(1.8-fold in Caco-2 and 4.1-fold in DLD-1). A dis-
tinctly stronger reduction of virus replication was
observed for CVB3-375TS(5+) when compared to
Fig. 3. Silencing of recombinant miR-375TS containing CVB3 by miR-375. (A) Expression of miR-375 after transfection of HEK293T cells.
HEK293T cells were transfected with a plasmid expressing miR-375 or control plasmid (miR-control) expressing the miR-216a. Twenty-four
hours later, expression of miR-375 was determined by real-time RT-PCR. The data were normalized against U6snRNA and are shown
relative to the expression of miR-375 in murine pancreas, which was arbitrarily set to 1. Mean values  SEM are displayed from one
experiment performed in triplicate. (B) Silencing miR-375TS containing CVB3 by miR-375. HEK293T cells were transfected as in 3a and
infected 24 h later with the indicated recombinant CVB3 at an MOI of 0.1. Virus replication was analyzed 24 h later by plaque assay. Left
diagram—recombinant CVB3 with miR-TS in the 30UTR. Right diagram—recombinant CVB3 with miR-TS at the 50-terminus of the CVB3
polyprotein encoding sequence. Mean values  SEM are displayed from two experiments performed, each in triplicate. Significance:
***P < 0.001; n.s. not significant.
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rCVB3.1 (21.7-fold in Caco-2 and 7.1-fold in DLD-1)
(Fig. 5A,B). Regarding cytotoxicity, Caco-2 cells were
moderately susceptible to lytic infection with CVB3-
375TS(3+) but completely resistant to CVB3-375TS(5+).
However, the strength of cytotoxicity induced by CVB3-
375TS(3+) was lower than for the parental rCVB3.1. In
DLD1 cells, only weak cell lysis was observed for
rCVB3.1, whereas the cells were completely resistant to
CVB3-375TS(3+) and CVB3-375(5+) (Fig. 5A,B). The
data indicate that the replication and the ability to
induce cytotoxicity in colorectal carcinoma cells are
maintained in both CVB3 equipped with miR-375TS.
However, compared to the parental rCVB3.1, CVB3-
375TS(3+) shows slightly and CVB3-miR375TS(5+)
moderately impaired performance. As lower replication
and cytotoxicity were also seen in miR-39TS control
viruses (Fig. 5A,B), the impairment of the miR-375TS
viruses seems to be not induced by a specific interaction
of miR-375TS with miR-375, which is expressed only at
low levels in both cell lines (Fig. 1A).
Fig. 4. Suppression of miR-375TS-containing CVB3 in pancreatic EndoC-bH1 cells. EndoC-bH1 cells were infected at an MOI of 1 of
the indicated recombinant CVB3 and cells were analyzed 24 h later. (A) Determination of virus titers by plaque assay. Fold changes
between individual samples are shown. Mean values  SEM are displayed from two experiments performed each in duplicate.
Significance: ***P < 0.001. (B) Determination of CVB3 VP1 and cellular proteins eIF4G, cleaved eIF4G, PARP, cleaved PARP, and
cleaved Caspase 3 by western blotting. c -tubulin was used as internal loading control. (C) Cytotoxicity of miR-375TS-containing CVB3.
EndoC-bH1 cells were infected at an MOI of 1 of the indicated viruses. Cytotoxicity was determined by XTT assay 48 h after infection.
Values measured for untreated cells were arbitrarily set to 100 and used to calculate the relative cytotoxicity of virally infected cells.
Significance: ****P < 0.0001. n.s., not significant. Mean values  SEM are displayed from three experiments out of a total of eight
samples.
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Discussion
CVB3 has potential as a new oncolytic virus for the
treatment of cancer. However, with exception of the
CVB3 variant PD [10,15], all CVB3 strains analyzed
so far also replicate in normal tissues, particularly in
the pancreas and the heart, where they induce tissue
injury and inflammation [13–15]. MiR-mediated virus
detargeting represents a powerful technique to prevent
Fig. 5. Replication and cytotoxicity miR-375TS-containing CVB3 in the colorectal carcinoma cell lines. (A) Replication and cytotoxicity in
Caco-2 cells. Caco-2 cells were infected at an MOI of 0.01 with the indicated viruses. Left—virus titers were measured in cell supernatants
by plaque assay 48 h after infection. Right—cytotoxicity was determined by XTT assay 72 h after infection as described under Fig. 4C.
Values measured for untreated cells were set as 100 and used to calculate cytotoxicity of virus-infected cells. Mean values  SEM are
displayed from two experiments each performed in duplicate. (B) Replication and cytotoxicity in DLD1 cells. DLD1 cells were infected at an
MOI of 100 with the indicated viruses. Left—virus titers were measured in cell culture supernatants 48 h after infection. Right—cytotoxicity
was determined by XTT assay 144 h after infection, as described under A. Fold changes between individual samples are shown.
Significance: *P < 0.05; **P < 0.01; ***P < 0.001. n.s., not significant. Mean values  SEM are displayed from two experiments each
performed in duplicate.
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oncolytic viruses from replicating in nontargeted tis-
sues, which makes this technique a valuable approach
to increase the safety of this type of cancer therapy
[23,34,35]. Addressing prevention of undesirable CVB3
replication in the heart by insertion of muscle-specific
miR-206TS and miR-133TS has been carried out suc-
cessfully [28], whereas attenuation of CVB3 in the pan-
creas and heart was achieved by insertion of miR-
34aTS into the CVB3 genome [14].
Our research focus is on the development of oncoly-
tic CVB3 for treatment of colorectal carcinomas [15].
Unfortunately, and in agreement with previous studies
[36,37], we found that miR-34a was highly expressed
in colorectal carcinoma cell lines, suggesting that a
CVB3 equipped with miR-34aTS would probably be
detargeted not only in the pancreas and the heart, but
also in the colorectal cancer cells, which would nega-
tively impact the outcome of the cancer treatment. As
miR for cardiac-specific attenuation of CVB3 has
already been defined [28] and may be easily used in the
context of oncolytic CVB3, here we focused on the
development of pancreas-attenuated CVB3. Therefore,
CVB3 was equipped with miR-TS complementary to
the miR-375, which we found is highly expressed in
the pancreas but is weakly expressed in colorectal car-
cinoma cell lines (Fig. 1A). We show that CVB3 vari-
ants engineered with miR-375TS were highly
susceptible to the pancreas-specifically expressed miR-
375. Virus replication was drastically reduced by sev-
eral orders of magnitude (up to 38 000-fold) in pancre-
atic cells expressing the miR-375 endogenously,
whereas virus replication and cytotoxicity were largely
retained in colorectal cancer cell lines. Moreover, by
evaluating sites for integration of miR-375TS, our data
reveal that both the 30UTR and, as shown here for the
first time, the protein coding region of the viral gen-
ome are suitable regions to make the virus sensitive to
the miR-375.
Despite the fact that our data indicate that insertion
of miR-TS into the viral genome per se slightly impairs
virus replication and cytotoxicity, the site of miR-TS
insertion is an additional crucial factor affecting silenc-
ing of the virus by the corresponding miRs. The geno-
mic structure of picornaviruses can be divided into a
50-UTR, the protein coding region, and a 30UTR, and
previously it was shown that CVB3 with miR-TS in
the 50-UTR and in the 30UTR are susceptible to their
corresponding miRs [14,23,27]. On the other hand, it
has also been shown that certain sections within the
50-UTR and 30UTR do not tolerate miR-TS insertion,
most likely because insertion of miR-TS disturbed
higher-order RNA structures of the viral genome [28].
In the present study, we pursued a new approach and
inserted the miR-375TS into the 50 terminus of the
polyprotein coding region of the CVB3 genome and
compared it to insertion immediately downstream of
the polyprotein stop codon in the 30UTR, which is
known to tolerate miR-TS [14]. Using the respective
CVB3 cDNA constructs, the recombinant viruses were
generated successfully, demonstrating that insertion of
the miR-375TS at the selected sites was tolerated by
the viruses. However, when comparing the suppression
in miR-375 expressing pancreatic cells, CVB3 contain-
ing miR-375TS in the 30UTR was suppressed far more
than in CVB3 containing miR-375TS at the 50 termi-
nus of the polyprotein coding region. Although the
underlying mechanism remains to be elucidated, it is
likely that the different sequences and resulting sec-
ondary structure flanking the miR-375TS sequence
may influence the binding, stability, or the activity of
the RNA-induced silencing complex (RISC), which is
important for degradation of the viral genome.
Because of the resistance of the investigated colorec-
tal carcinoma cell lines against the strain rCVB3.1, a
reliable assessment regarding the differences in cyto-
toxic activity of miR-375TS viruses in the cancer cells
was not possible. However, our data reveal that both
viruses replicated in colorectal carcinoma cells, but the
performance of the CVB3 with miR-375TS in the
30UTR was better. On the other hand, this viral con-
struct was not as effective as its parental rCVB3.1. In
contrast to our data, other studies found very similar
replication of parental and miR-TS-bearing oncolytic
picornaviruses [14,27,28,35]. We can exclude suppres-
sion of miR-375TS by the rarely expressed miR-375 in
colorectal carcinoma cells, since the miR-39TS control
viruses did not replicate as well, suggesting that indi-
vidual differences to miR-TS and the surrounding
sequences used in our study may play a role in the
lower activity we observed.
After infection, CVB3 generates a minus-strand
RNA intermediate, from which multiple copies of viral
plus-strand RNA copies are transcribed [38]. It has
been shown that in infected cells there are far more
plus strands than minus strands [39], which makes tar-
geting of the minus-strand antigenome attractive for a
miR-detargeting strategy. Our data demonstrate that
the minus strand of CVB3, when equipped with miR-
375TS, cannot be targeted by the corresponding miR-
375. This observation is in line with an earlier report
by Schubert et al. showing failure of inhibition of
CVB3 replication when the viral minus strand was tar-
geted by an siRNA [40]. It should be noted that a pre-
vious study found some reduction of viral replication
in a miR-142TS containing CVA21 when targeting the
minus-strand antigenome. However, compared to
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targeting the plus-strand sense genome, the efficacy
was 1000-fold lower in this study [35].
Evolution of viruses leads to an optimized viral life
cycle. MiR-TS, when inserted into the virus genome,
counteracts this process and therefore evolutionary
pressure will work toward inactivating the miR-TS.
There are two principal mechanisms through which
the inhibition of the additional sequences can be coun-
tered by picornaviruses, either by acquiring mutations
within the miR-TS [23] or by elimination of the miR-
TS through homologous genomic recombination [41].
In tumor-bearing mice which had been treated with
miR-regulated CVA21 for an extended period of time,
mutations were detected but not deletion of the miR-
TS [23,35], indicating that mutations are more easily
acquired than deletion of the miR-TS. Interestingly,
the mutations did not or only slightly affected the sen-
sitivity of the virus for the miR [23], probably as mul-
tiple copies of a miR-TS were inserted into the viral
genome and only single copies were mutated. As a
consequence of these experiences, we inserted three
copies of miR-375TS into our viruses in order to
reduce the risk of development of viral escape
mutants.
Unfortunately, the miR-375TS CVB3 described here
showed only weak replication and cytotoxicity in col-
orectal carcinoma cells, which makes it unsuitable for
further development as an oncolytic virus for the ther-
apy of colorectal carcinomas. Recently, we investigated
other CVB3 strains (Nancy, 31-1-93, H3, and PD) for
their oncolytic potential in colorectal carcinomas [15].
All of them had distinct antitumor effects, but also
induced side effects, including severe damage to the
pancreas. Equipping these viruses with miR-375TS
may improve their safety and thereby make them can-
didates for the therapy of colorectal cancer. Studies
are underway to prove it.
In conclusion, we demonstrate here that insertion of
miR-375TS into the genome of CVB3 attenuates the
virus in pancreatic cells while preserving its ability to
replicate in colorectal carcinoma cells. Moreover, our
study reveals that the 30UTR and the 50 terminus of
the polyprotein protein coding sequence of CVB3 are
suitable sites for the insertion of miR-TS, with inser-
tion into the 30UTR enabling stronger attenuation of
the virus in the nontargeted pancreatic cells.
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